Matthew Fowler


Analysis shows strength of abiraterone/ADT efficacy in non-metastatic prostate cancer

January 18, 2022

The combination of abiraterone acetate, prednisolone, and androgen deprivation therapy (ADT) with or without enzalutamide delivers a strong metastasis-free survival boost versus treatment with ADT alone in patients with high-risk non-metastatic prostate cancer.

2-year data for abiraterone regimen show sustained OS benefit in nonmetastatic prostate cancer

September 19, 2021

"2 years of abiraterone-based therapy significantly improves metastasis-free survival and overall survival of high-risk nonmetastatic prostate cancer starting androgen deprivation therapy and should be now considered a new standard of care,” said Gerhardt Attard, MD, FRCP, PhD.